Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial.
Heath economic evaluation; Hyaluronic acid; Osteoarthritis; Immunology and Allergy; Rheumatology
Abstract :
[en] INTRODUCTION: In a recent randomized placebo-controlled trial, a single intra-articular injection of a high and low molecular weight hyaluronic acid formulation (HA-HL) was shown to be effective in providing a clinically meaningful reduction in pain and functional limitation up to 24 weeks in subjects with painful knee osteoarthritis (OA). The objective of this post hoc analyses is to assess the cost-effectiveness of HA-HL compared with placebo using individual patient data from this clinical trial in a Swiss health care perspective.
METHODS: A total of 692 patients fulfilling the inclusion criteria were randomly allocated to HA-HL or placebo groups. Each patient received one intra-articular injection of HA-HL or placebo at baseline and was then followed-up for a total duration of 24 weeks with five follow-up visits (i.e., after weeks 1, 6, 12, 18, and 24). The EQ-5D-5L five-point verbal Likert scale was used to calculate the health utility and the related quality-adjusted life-years (QALYs) using the area-under-the-curve (AUC) method. For the costs, the price of HA-HL in Switzerland was used. The primary threshold for the incremental cost/effectiveness ratio (ICER) below which HA-HL was considered as cost-effective was 91,540 Swiss francs (CHF) per QALY (i.e., US $100,000).
RESULTS: No significant difference between the baseline characteristics of the HA-HL group and the placebo group was observed. With a mean ICER of 27,212 CHF per QALY (95% CI 20,135-34,289), HA-HL was considered as cost-effective compared to placebo. Sensitivity analyses (e.g., using lower or upper limit prices or using other threshold values) gave similar results, i.e., ICERs far below the threshold values of cost-effectiveness.
CONCLUSIONS: These results confirm the role of HA-HL as a cost-effective therapeutic option in the management of OA. However, more studies taking into account the utilization of other health care resources are needed.
Disciplines :
Public health, health care sciences & services
Author, co-author :
BRUYERE, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Honvo, Germain ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial.
Leyland KM, Gates LS, Sanchez-Santos MT, Nevitt MC, Felson D, Jones G, Jordan JM, Judge A, Prieto-Alhambra D, Yoshimura N, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021;33:529–45. 10.1007/s40520-020-01762-2. DOI: 10.1007/s40520-020-01762-2
Llopart-Carles N, García-López S, Rejas-Gutierrez J. Disability-adjusted life expectancy lost due to pain severity and usual analgesic treatment among older adults with osteoarthritis in Spain. Aging Clin Exp Res. 2021;33:1285–95. 10.1007/s40520-020-01630-z. DOI: 10.1007/s40520-020-01630-z
Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27:1578–89. 10.1016/j.joca.2019.06.011. DOI: 10.1016/j.joca.2019.06.011
Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, Al-Daghri NM, Herrero-Beaumont G, Martel-Pelletier J, Pelletier JP, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337–50. 10.1016/j.semarthrit.2019.04.008. DOI: 10.1016/j.semarthrit.2019.04.008
Phillips M, Bhandari M, Grant J, Bedi A, Trojian T, Johnson A, Schemitsch E. A systematic review of current clinical practice guidelines on intra-articular hyaluronic acid, corticosteroid, and platelet-rich plasma injection for knee osteoarthritis: an international perspective. Orthop J Sports Med. 2021;9:23259671211030270. 10.1177/23259671211030272. DOI: 10.1177/23259671211030272
Migliore A, Blicharski T, Plebanski R, Zegota Z, Gyula G, Rannou F, Reginster JY. Knee osteoarthritis pain management with an innovative high and low molecular weight hyaluronic acid formulation (HA–HL): a randomized clinical trial. Rheumatol Ther. 2021;8:1617–36. 10.1007/s40744-021-00363-3. DOI: 10.1007/s40744-021-00363-3
Bedenbaugh AV, Bonafede M, Marchlewicz EH, Lee V, Tambiah J. Real-world health care resource utilization and costs among US patients with knee osteoarthritis compared with controls. ClinicoEcon Outcomes Res CEOR. 2021;13:421–35. 10.2147/ceor.s302289. DOI: 10.2147/ceor.s302289
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res Int J Qual Life Aspects Treat Care Rehabil. 2011;20:1727–36. 10.1007/s11136-011-9903-x. DOI: 10.1007/s11136-011-9903-x
Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36:663–74. 10.1007/s40273-018-0615-8. DOI: 10.1007/s40273-018-0615-8
Versteegh MM, Vermeulen KM, Evers SM, De Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health J Int Soc Pharmacoecon Outcomes Res. 2016;19:343–52. 10.1016/j.jval.2016.01.003. DOI: 10.1016/j.jval.2016.01.003
Andrade LF, Ludwig K, Goni JMR, Oppe M, de Pouvourville G. A French value set for the EQ-5D-5L. Pharmacoeconomics. 2020;38:413–25. 10.1007/s40273-019-00876-4. DOI: 10.1007/s40273-019-00876-4
Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018;11:1447828. 10.1080/16549716.2018.1447828. DOI: 10.1080/16549716.2018.1447828
Beaudart C, Lengelé L, Leclercq V, Geerinck A, Sanchez-Rodriguez D, Bruyère O, Reginster JY. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80:1947–59. 10.1007/s40265-020-01423-8. DOI: 10.1007/s40265-020-01423-8
Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, Jüni P, Trelle S. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum. 2007;57:1410–8. 10.1002/art.23103. DOI: 10.1002/art.23103
Galluccio F, D’Angela D, Polistena B, Porta F, Barskova T, Tofani L, Spandonaro F, Matucci-Cerinic M. Comparison of three treatment protocols with intra-articular low or intermediate molecular weight hyaluronic acid in early symptomatic knee osteoarthritis. Therap Adv Musculoskelet Dis. 2021. 10.1177/1759720x21994024. DOI: 10.1177/1759720x21994024
Li M, Huang Z, Wang S, Di Z, Zhang J, Liu H. Intra-articular injections of platelet-rich plasma vs. hyaluronic acid in patients with knee osteoarthritis: preliminary follow-up results at 6-months. Exp Therap Med. 2021;21:598. 10.3892/etm.2021.10030. DOI: 10.3892/etm.2021.10030
Samuelson EM, Ebel JA, Reynolds SB, Arnold RM, Brown DE. The cost-effectiveness of platelet-rich plasma compared with hyaluronic acid injections for the treatment of knee osteoarthritis. Arthrosc J Arthrosc Relat Surg. 2020;36:3072–8. 10.1016/j.arthro.2020.07.027. DOI: 10.1016/j.arthro.2020.07.027
Hermans J, et al. Cost-utility analysis of high molecular weight hyaluronic acid for knee osteoarthritis in everyday clinical care in patients at a working age: an economic evaluation of a randomized clinical trial. Arthritis Care Res (Hoboken). 2018;70(1):89–97. DOI: 10.1002/acr.23242
Thomas T, Amouroux F, Vincent P. Intra articular hyaluronic acid in the management of knee osteoarthritis: pharmaco-economic study from the perspective of the national health insurance system. PLoS One. 2017;12: e0173683. 10.1371/journal.pone.0173683. DOI: 10.1371/journal.pone.0173683